The BioPharm market is being driven by strong governmental support, including the creation of intellectual property protection laws, economic development zones, and relevant university curriculum.

Encyclopedia of Pharmaceutical Technology
Editor(s) - James Swarbrick
Presenting authoritative and engaging articles on all aspects of drug development, dosage, manufacturing, and regulation, this Third Edition enables the pharmaceutical specialist and novice alike to keep abreast of developments in this rapidly evolving and highly competitive field. A dependable reference tool and constant companion for years to come, the Third Edition will offer completely new entries that cover critical issues in the field such as the impact of genomics, biotechnology, and implants on drug discovery, targeting, delivery, and formulation.

Genes in Development
Author(s) - Eva M. Neumann-Held , Christoph Rehmann-Sutter
In light of scientific advances such as genomics, predictive diagnostics, genetically engineered agriculture, nuclear transfer cloning, and the manipulation of stem cells, the idea that genes carry predetermined molecular programs or blueprints is pervasive. Yet new scientific discoveries—such as rna transcripts of single genes that can lead to the production of different compounds from the same pieces of dna—challenge the concept of the gene alone as the dominant factor in biological development.

Pharmaceutical Economics and Policy
Author(s) - Stuart O. Schweitzer
The pharmaceutical industry is praised as a world leader in high technology innovation and the creator of products that increase both longevity and quality of life for people throughout the world. At the same time, the industry is also criticized for its marketing and pricing practices and for its apparent anticompetitive responses to generic competition. Even its research and development priorities are criticized as being too closely driven by the goal of maximizing shareholder value, rather than the health of the public.

The aim of this study was to investigate the use of thermotropic liquid crystalline (TLC) blends of 4-pentyl-4′-cyanobiphenyl (K15) and 4-heptyl-4′-cyanobiphenyl (K21) with appropriate nematic to isotropic phase temperature (Tn − i) just above body temperature as a temperature-modulated drug permeation system.

Combating Generics - Pharmaceutical Brand Defense for 2007

Pharma Risk Managers: ERM Is In Your Future
Pharma risk managers and compliance professionals face increasing regulatory scrutiny and market pressures that amplify both business and operational risk.